| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d904e68b6e0b4f6ce1d0cbcd02d8a99 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-26 |
| filingDate |
2007-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9928f6d19836e7748c345a5ea8ea96c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7367f83167e935a0fb0c37e488fddfb2 |
| publicationDate |
2009-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2306595-B1 |
| titleOfInvention |
NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 . |
| abstract |
5- (2 - {[6- (2,2-Difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl) -8-hydroxyquinoline-2 (1 H ) -one napadisylate salt as an adrenergic receptor agonist β2. The present invention relates to novel crystalline salts of naphthalen-1,5-disulfonic acid (napadisylates) of 5- (2 - {[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl ) -8-hydroxyquin nolin-2 (1 H ) -one, its enantiomers and its solvates of general formula I. The invention also relates to pharmaceutical compositions comprising crystalline salts, methods of using them to treat respiratory diseases associated with the activity of adrenergic receptors. beta2, and procedures and intermediates useful for preparing such salts.n n n n 100 |
| priorityDate |
2007-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |